

## BRD3-2 (GST) (Bromodomain containing protein 3 (RING3L), bromodomain 2)

**CATALOG NO.:** RD-11-164

**LOT NO.:**


**DESCRIPTION:** Human recombinant BRD3, bromodomain-2 (residues 306-416; Genbank Accession # NM\_007371; MW = 40.1 kDa) expressed as an N-terminal GST fusion protein in *E. coli*. BRD3, like other human members of the BET family of chromatin-binding proteins (BRD2, BRD4, BRDT), comprises two bromodomains (see reviews<sup>1,2</sup>), protein modules that bind  $\epsilon$ -N-acetyllysine residues<sup>3,4</sup>. Recent results suggest an important role for BRD3 in linking acetylation of both histones and non-histone proteins to gene transcription. When overexpressed in 293 cells, BRD3, along with BRD2, binds the hyperacetylated chromatin of transcribed genes, regions enriched in acetylated histone H4 lysine-5 (H4K5Ac), H4K12Ac, H3K14Ac, but deficient in H4K16Ac and H3K9me<sup>5</sup>. In an *in vitro* RNA polymerase II transcription system, binding of either BRD3 or BRD2 to a chromatin template assembled with hyperacetylated histones enabled transcription through the nucleosomes<sup>5</sup>. Although BRD3-2 has been shown to bind tetracetylated histone H4 tail sequence (H4K5AcK8AcK12AcK16Ac), the interaction is weaker than that of BRD3-1<sup>6</sup>. The BET family inhibitor, I-BET151, has shown efficacy in mouse models of MLL-fusion leukemias, displacing BRD3 and BRD4 from chromatin and inhibiting transcription of genes, e.g. *BCL2*, upregulated by the MLL-fusions<sup>7</sup>.

**PURITY:** >95% by SDS-PAGE


**SUPPLIED AS:**  $\sim$   $\mu$ g/ $\mu$ L in 20 mM Tris/HCl, pH 7.5, 150 mM NaCl, 1.0 mM TCEP, 10% glycerol (w/v) as determined by OD<sub>280</sub>

**STORAGE:** -70°C. Thaw quickly and store on ice before use. The remaining, unused, undiluted protein should be snap frozen, for example in a dry/ice ethanol bath or liquid nitrogen. Minimize freeze/thaws if possible, but very low volume aliquots (<5  $\mu$ l) or storage of diluted enzyme is not recommended.

**REFERENCES:** 1) B. Florence & D.V. Faller *Front. Biosci.* 2001 **6** D1008; 2) S.-Y. Wu & C.-M. Chiang *J. Biol. Chem.* 2007 **282** 13141; 3) D.J. Owen *et al. EMBO J.* 2000 **19** 6141; 4) L. Zeng & M.-M. Zhou *FEBS Lett.* 2002 **513** 124; 5) G. LeRoy *et al. Mol. Cell* 2008 **30** 51; 6) J.M. Lamonica *et al. Proc. Natl. Acad. Sci. USA* 2011 **108** E159; 7) M.A. Dawson *et al. Nature* 2011 **478** 529



**Coomassie blue stained SDS-PAGE (4-12% acrylamide) of 3  $\mu$ g of RBC BRD3-2 (GST).** MW markers (left lane) are, from top, 220, 160, 120, 100, 90, 80, 70, 60, 50, 40, 30, 25, 20, 15 & 10 kDa.



**Differential Scanning Fluorimetry of RBC BRD3-2 (GST) in Presence or Absence of (+)-JQ1.** Thermal denaturation of BRD3-2 (GST) is detected (CFX384™ Touch thermal cycler, 'FRET' channel; Bio-Rad) by increased binding and fluorescence of the dye SYPRO® Orange (Life Technologies). Addition of the BET bromodomain inhibitor/ligand (+)-JQ1 (10  $\mu$ M) stabilizes the protein folding and shifts the  $T_m$  (inflection point) from 45°C to 50°C.

This product is not intended for therapeutic or diagnostic use in animals or in humans.

Reaction Biology

1 Great Valley Parkway, Malvern PA, USA 19355

requests@reactionbiology.com www.reactionbiology.com